Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › ASC35 / ASC36

ASC35 / ASC36

GIP/GLP-1 + amylin (monthly co-formulation) · s.c. monthly · Ascletis

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 0 registered trials · see on the pipeline board

Summary

Also known as
Ascletis
Mechanism
GIP/GLP-1 + amylin (monthly co-formulation)
Route
s.c. monthly
Company
Ascletis
Highest development stage
phase 1
Status (as of data cut)
Phase 1 single and multiple ascending dose study recruiting since Aug 2026; preclinical data at EASD 2026 verify
Next milestone
Phase 1 results

Sources for the status

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: ASC35 / ASC36. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/asc35-asc36/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.